Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia

Autor: Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, Hazaa Al Zahrani, Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, Amr Hanbali
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Annals of Saudi Medicine, Vol 41, Iss 4, Pp 198-205 (2021)
Druh dokumentu: article
ISSN: 0256-4947
0975-4466
DOI: 10.5144/0256-4947.2021.198
Popis: BACKGROUND: In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT. OBJECTIVES: Determine the demographic characteristics of MM patients and the outcomes of ASCT. DESIGN: Retrospective. SETTING: Tumor registry database of major tertiary cancer care center in Riyadh. PATIENTS AND METHODS: We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015. MAIN OUTCOME MEASURES: The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS). SAMPLE SIZE: 169 patients with newly diagnosed MM. RESULTS: The median age at diagnosis was 51 years (range 23–69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (
Databáze: Directory of Open Access Journals
Externí odkaz: